ABBV - AbbVie Inc.
Close
174.83
0.250 0.143%
Share volume: 105,851
Last Updated: Fri 10 Jan 2025 08:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.49%
PREVIOUS CLOSE
CHG
CHG%
$174.58
0.25
0.14%
Fundamental analysis
37%
Profitability
29%
Dept financing
33%
Liquidity
11%
Performance
52%
Performance
5 Days
-2.43%
1 Month
1.14%
3 Months
-10.47%
6 Months
2.87%
1 Year
7.86%
2 Year
15.08%
Key data
Stock price
$174.83
DAY RANGE
$173.38 - $177.51
52 WEEK RANGE
$156.35 - $207.32
52 WEEK CHANGE
$8.48
DIVIDEND
$1.55
EX-DIVIDEND DATE
07/15/2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.
Recent news